Plus Therapeutics Updates on Positive Clinical Data, FDA Alignment for Accelerated Approval, and Commercial Relaunch

summarizeSummary

Plus Therapeutics announced significant clinical trial progress for its REYOBIQ radiotherapeutic, including positive survival data and FDA alignment on an accelerated approval pathway for Leptomeningeal Metastases, alongside the commercial relaunch of its CNSide diagnostic with national payor agreements.

check_boxKey Events

• Positive REYOBIQ Clinical Data

  The ReSPECT-LM Phase 1 trial showed a median overall survival (mOS) of 9 months, compared to 4-6 months for standard of care. The ReSPECT-GBM Phase 1 trial demonstrated 17 months mOS for patients receiving therapeutic doses (>100 Gy) versus 8 months for standard of care, with favorable interim Phase 2 data.

• FDA Alignment on Accelerated Approval Pathway

  The FDA indicated that accelerated approval may be appropriate for REYOBIQ in Leptomeningeal Metastases and aligned with the company on a randomized controlled trial design, providing a clear regulatory path forward.

• CNSide Commercial Relaunch and Payor Agreements

  The CNSide diagnostic platform is set for a commercial relaunch in Q3 2025, with initial national coverage agreements already secured with UnitedHealthcare and Humana, covering 67 million lives.

• Non-Dilutive Funding for Pediatric Trial

  The ReSPECT-PBC pediatric brain cancer Phase 1 trial, expected to enroll in Q1 2026, is supported by a $3.0 million award from the U.S. Department of Defense.

auto_awesomeAnalysis

This 8-K filing, incorporating an updated corporate presentation, provides a comprehensive and highly positive overview of Plus Therapeutics' pipeline and commercial strategy. The clinical data for REYOBIQ in both Leptomeningeal Metastases (LM) and recurrent Glioblastoma (rGBM) show significant improvements in median overall survival compared to standard of care, de-risking these programs. Crucially, the FDA's feedback on the ReSPECT-LM trial, indicating that accelerated approval may be appropriate and aligning on a randomized controlled design, provides a clear and expedited regulatory pathway. The commercial relaunch of CNSide, coupled with initial national coverage agreements, signals a tangible path to revenue generation. The non-dilutive funding for the pediatric brain cancer trial further strengthens the company's financial position and expands its pipeline. These combined updates represent substantial progress across multiple key programs, significantly enhancing the company's investment thesis and future prospects.